Notable operates a platform that tests patient‐derived cancer cells ex-vivo and predicts which drugs or drug combinations a specific patient population is most likely to respond to within five days. This insight helps oncologists steer patients toward the most promising clinical trials and allows pharmaceutical partners to design more targeted and efficient studies. The technology has been validated in multiple independent clinical studies run by Stanford University, MD Anderson Cancer Center, UCSF, Rady Children’s Hospital, and Texas Children’s Hospital. The company plans to use its latest capital to further advance development of the platform, deepen clinical collaborations, and expand partnerships with drug developers. Founded by Matt De Silva and based in Foster City, California, Notable positions itself at the intersection of precision oncology and drug development. Including the latest Series B, the company has secured more than $55 million in total funding to date, underscoring strong investor confidence in its approach.

Total raised

$50M

Funding rounds

2

Latest round

Series B

Latest activity

Jul 2019